A treatise on the law of libel and the liberty of the press; showing the origin, use, and abuse of the law of libel: with copious notes and references to authorities in Great Britain and the United States: as applicable to individuals and to political and ecclesiastical bodies and principles.

Microfilm. Ann Arbor, Mich. University Microfilms (n.d.) (American Culture Series, Reel 238.4)

English Causes célèbres; or, Reports of remarkable trials.

Mode of access: Internet.

A report of the trail of the cause of John Taylor vs. Edward C. Delavan : prosecuted for alleged libel ; tried at the Albany circuit, April, 1940 ; and Mr. Delavan's correspondence with the ex. committee of the Albany city temperance society, &c.

"This action ... is brought for two publications in the Evening journal, in the month of February, 1835 ... The declaration sets forth that the defendant meant to charge that impure, dirty and filthy water ... had, for years, been carted to the malt-house of the plaintill; ant that he had been guilty of using that water in preparing barley for malt."--p. 45.

Celebrated trials and remarkable cases of criminal jurisprudence from the earliest records to the year 1825.

On verso of each t.p.: London, Shackell and Arrowsmith; at end of v.1: Printed by W. Lewis; at end of v.2: Shackell and Arrowsmith; at end of v.3: J. and C. Adlard, printers; at end of v.4, and at foot of p.576; v.6: D. Sidney & Co., printers; at end of v.5: Whiting and Branston.

Report of Board on comparative trials of the scout cruisers Birmingham--Salem--Chester, December 22, 1909.

On seal: Navy Department, United States of America.

The law of unfair business competition, including chapters on trade secrets and confidential business relations; unfair interference with contracts; libel and slander of articles of merchandise, trade names, and business credit and reputation,

Mode of access: Internet.

Brickwood's Sackett on Instructions to juries; containing a treatise on jury trials and appeals with forms of approved instructions and charges annotated; also erroneous instructions with comment of the court in condemning them ...

Paged continuously.

Hyatt on trials; a treatise on the trial of civil and criminal cases in state and federal courts, with complete index and table of cases, /

Mode of access: Internet.

A combined analysis of two randomized controlled trials evaluating the effect of Mindfulness-Based Stress Reduction on self-reported emotional experience and physiological symptoms among Veterans with Posttraumatic Stress Disorder

Thesis (Master's)--University of Washington, 2016-06

Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-I trials

Objectives: To investigate the effectiveness of valerian for the management of chronic insomnia in general practice. Design: Valerian versus placebo in a series of n-of-1 trials, in Queensland, Australia. Results: Of 42 enrolled patients, 24 (57%) had sufficient data for inclusion into the n-of-1 analysis. Response to valerian was fair for 23 (96%) participants evaluating their 'energy level in the previous day' but poor or modest for all 24 (100%) participants' response to 'total sleep time' and for 23 (96%) participants' response to 'number of night awakenings' and 'morning refreshment'. As a group, the proportion of treatment successes ranged from 0.35 (95% CI 0.23, 0.47) to 0.55 (95% CI 0.43, 0.67) for the six elicited outcome sleep variables. There was no significant difference in the number (P = 0.06), distribution (P = 1.00) or severity (P = 0.46) of side effects between valerian and placebo treatments. Conclusions: Valerian was not shown to be appreciably better than placebo in promoting sleep or sleep-related factors for any individual patient or for all patients as a group. (C) 2003 Elsevier Ltd. All rights reserved.

OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative had developed two sets of responder criteria to present the results of changes after treatment in three symptomatic domains (pain, function, and patient's global assessment) as a single variable for clinical trials (1). For each domain, a response was defined by both a relative and an absolute change, with different cut-offs with regard to the drug, the route of administration and the OA localization. Objective: To propose a simplified set of responder criteria with a similar cut-off, whatever the drug, the route or the OA localization. Methods: Data driven approach: (1) Two databases were considered The 'elaboration' database with which the formal OARSI sets of responder criteria were elaborated and The 'revisit' database. (2) Six different scenarios were evaluated: The two formal OARSI sets of criteria Four proposed scenarios of simplified sets of criteria Data from clinical randomized blinded placebo controlled trials were used to evaluate the performances of the two formal scenarios with two different databases ('elaboration' versus 'revisit') and those of the four proposed simplified scenarios within the 'revisit' database. The placebo effect, active effect, treatment effect, and the required sample arm size to obtain the placebo effect and the active treatment effect observed were the performances evaluated for each of the six scenarios. Experts' opinion approach: Results were discussed among the participants of the OMERACT VI meeting, who voted to select the definite OMERACT-OARSI set of criteria (one of the six evaluated scenarios). Results: Data driven approach: Fourteen trials totaling 1886 CA patients and fifteen studies involving 8164 CA patients were evaluated in the 'elaboration' and the 'revisit' databases respectively. The variability of the performances observed in the 'revisit' database when using the different simplified scenarios was similar to that observed between the two databases ('elaboration' versus 'revisit') when using the formal scenarios. The treatment effect and the required sample arm size were similar for each set of criteria. Experts' opinion approach: According to the experts, these two previous performances were the most important of an optimal set of responder criteria. They chose the set of criteria considering both pain and function as evaluation domain and requiring an absolute change and a relative change from baseline to define a response, with similar cut-offs whatever the drug, the route of administration or the CA localization. Conclusion: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for CA clinical trials. Other studies, using other sets of CA patients, are required in order to further validate this proposed OMERACT - OARSI set of criteria. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.